Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Neuroscience Bulletin
Erschienen in:

01.04.2019 | Original Article

NMDA Receptor Antagonist MK801 Protects Against 1-Bromopropane-Induced Cognitive Dysfunction

verfasst von: Lin Xu, Xiaofei Qiu, Shuo Wang, Qingshan Wang, Xiu-Lan Zhao

Erschienen in: Neuroscience Bulletin | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Occupational exposure to 1-bromopropane (1-BP) induces learning and memory deficits. However, no therapeutic strategies are currently available. Accumulating evidence has suggested that N-methyl-D-aspartate receptors (NMDARs) and neuroinflammation are involved in the cognitive impairments in neurodegenerative diseases. In this study we aimed to investigate whether the noncompetitive NMDAR antagonist MK801 protects against 1-BP-induced cognitive dysfunction. Male Wistar rats were administered with MK801 (0.1 mg/kg) prior to 1-BP intoxication (800 mg/kg). Their cognitive performance was evaluated by the Morris water maze test. The brains of rats were dissected for biochemical, neuropathological, and immunological analyses. We found that the spatial learning and memory were significantly impaired in the 1-BP group, and this was associated with neurodegeneration in both the hippocampus (especially CA1 and CA3) and cortex. Besides, the protein levels of phosphorylated NMDARs were increased after 1-BP exposure. MK801 ameliorated the 1-BP-induced cognitive impairments and degeneration of neurons in the hippocampus and cortex. Mechanistically, MK801 abrogated the 1-BP-induced disruption of excitatory and inhibitory amino-acid balance and NMDAR abnormalities. Subsequently, MK801 inhibited the microglial activation and release of pro-inflammatory cytokines in 1-BP-treated rats. Our findings, for the first time, revealed that MK801 protected against 1-BP-induced cognitive dysfunction by ameliorating NMDAR function and blocking microglial activation, which might provide a potential target for the treatment of 1-BP poisoning.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kim Y, Park J, Moon Y. Hematopoietic and reproductive toxicity of 2-bromopropane, a recently introduced substitute for chlorofluorocarbons. Toxicol Lett 1999, 108: 309–313.CrossRefPubMed
2.
Moon HI, Shin S, Byeon SH. Exposure monitoring and health risk assessment of 1-bromopropane as a cleaning solvent in the workplace. Hum Ecol Risk Assess 2015, 21: 744–752.CrossRef
3.
Wang TH, Wu ML, Wu YH, Tsai WJ, Lin KP, Wang CL, et al. Neurotoxicity associated with exposure to 1-bromopropane in golf-club cleansing workers. Clin Toxicol 2015, 53: 823–826.CrossRef
4.
Samukawa M, Ichihara G, Oka N, Kusunoki S. A case of severe neurotoxicity associated with exposure to 1-bromopropane, an alternative to ozone-depleting or global-warming solvents. Arch Intern Med 2012, 172: 1257–1260.CrossRefPubMed
5.
Ichihara G, Kitoh J, Yu X, Asaeda N, Iwai H, Kumazawa T, et al. 1-Bromopropane, an alternative to ozone layer depleting solvents, is dose-dependently neurotoxic to rats in long-term inhalation exposure. Toxicol Sci 2000, 55: 116–123.CrossRefPubMed
6.
Sohn YK, Suh JS, Kim JW, Seo HH, Kim JY, Kim HY, et al. A histopathologic study of the nervous system after inhalation exposure of 1-bromopropane in rat. Toxicol Lett 2002, 131: 195–201.CrossRefPubMed
7.
Guo Y, Yuan H, Jiang LL, Yang JL, Zeng T, Xie KQ, et al. Involvement of decreased neuroglobin protein level in cognitive dysfunction induced by 1-bromopropane in rats. Brain Res 2015, 1600: 1–16.CrossRefPubMed
8.
Zhong ZX, Zeng T, Xie KQ, Zhang CL, Chen JJ, Bi Y, et al. Elevation of 4-hydroxynonenal and malondialdehyde modified protein levels in cerebral cortex with cognitive dysfunction in rats exposed to 1-bromopropane. Toxicology 2013, 306: 16–23.CrossRefPubMed
9.
Chalupka S. Reducing workplace exposure to 1-bromopropane. Workplace Health Saf 2014, 62: 128.CrossRefPubMed
10.
Ichihara G, Li W, Shibata E, Ding X, Wang H, Liang Y, et al. Neurologic abnormalities in workers of a 1-bromopropane factory. Environ Health Perspect 2004, 112: 1319–1325.CrossRefPubMedPubMedCentral
11.
Ichihara G, Miller JK, Ziolkowska A, Itohara S, Takeuchi Y. Neurological disorders in three workers exposed to 1-bromopropane. J Occup Environ Med 2002, 44: 1–7.CrossRef
12.
Majersik JJ, Caravati EM, Steffens JD. Severe neurotoxicity associated with exposure to the solvent 1-bromopropane (n-propyl bromide). Clin Toxicol (Phila) 2007, 45: 270–276.CrossRef
13.
Yu X, Ichihara G, Kitoh J, Xie Z, Shibata E, Kamijima M, et al. Neurotoxicity of 2-bromopropane and 1-bromopropane, alternative solvents for chlorofluorocarbons. Environ Res 2001, 85: 48–52.CrossRefPubMed
14.
Soto D, Altafaj X, Sindreu C, Bayes A. Glutamate receptor mutations in psychiatric and neurodevelopmental disorders. Commun Integr Biol 2014, 7: e27887.CrossRefPubMedPubMedCentral
15.
Bi H, Sze CI. N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer’s disease. J Neurol Sci 2002, 200: 11–18.CrossRefPubMed
16.
17.
18.
Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease. J Neurol Sci 2001, 182: 151–159.CrossRefPubMed
19.
Chang YC, Kim HW, Rapoport SI, Rao JS. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem Res 2008, 33: 2318–2323.CrossRefPubMedPubMedCentral
20.
Rammes G, Mattusch C, Wulff M, Seeser F, Kreuzer M, Zhu K, et al. Involvement of GluN2B subunit containing N-methyl-D-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (Aβ) in murine models of Alzheimer’s disease (AD). Neuropharmacology 2017, 123: 100–115.CrossRefPubMed
21.
Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 2009, 157: 1301–1317.CrossRefPubMedPubMedCentral
22.
Fang M, Li J, Tiu SC, Zhang L, Wang M, Yew DT. N-methyl-D-aspartate receptor and apoptosis in Alzheimer’s disease and multiinfarct dementia. J Neurosci Res 2005, 81: 269–274.CrossRefPubMed
23.
Fueta Y, Ishidao T, Arashidani K, Endo Y, Hori H. Hyperexcitability of the hippocampal CA1 and the dentate gyrus in rats subchronically exposed to a substitute for chlorofluorocarbons, 1-bromopropane vapor. J Occup Health 2002, 44: 156–165.CrossRef
24.
Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 2017, 11: 63.PubMedPubMedCentral
25.
Fang X, Sun D, Wang Z, Yu Z, Liu W, Pu Y, et al. MiR-30a positively regulates the inflammatory response of microglia in experimental autoimmune encephalomyelitis. Neurosci Bull 2017, 33: 603–615.CrossRefPubMedPubMedCentral
26.
Gonzalez H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 2014, 274: 1–13.CrossRefPubMed
27.
Thomas DM, Kuhn DM. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005, 1050: 190–198.CrossRefPubMed
28.
Rosi S, Vazdarjanova A, Ramirez-Amaya V, Worley PF, Barnes CA, Wenk GL. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142: 1303–1315.CrossRefPubMed
29.
Subramanian K, Mohideen SS, Suzumura A, Asai N, Murakumo Y, Takahashi M, et al. Exposure to 1-bromopropane induces microglial changes and oxidative stress in the rat cerebellum. Toxicology 2012, 302: 18–24.CrossRefPubMed
30.
Han EH, Yang JH, Kim HK, Choi JH, Khanal T, Do MT, et al. 1-Bromopropane up-regulates cyclooxygenase-2 expression via NF-kappaB and C/EBP activation in murine macrophages. Food Chem Toxicol 2012, 50: 1616–1622.CrossRefPubMed
31.
Xu YP, Wang S, Jiang LL, Wang H, Yang YL, Li M, et al. Identify melatonin as a novel therapeutic reagent in the treatment of 1-bromopropane(1-BP) intoxication. Medicine 2016, 95: 8.CrossRef
32.
Wang S, Irving G, Jiang L, Wang H, Li M, Wang X, et al. Oxidative stress mediated hippocampal neuron apoptosis participated in carbon disulfide-induced rats cognitive dysfunction. Neurochem Res 2017, 42: 583–594.CrossRefPubMed
33.
Wu X, Wang R, Jiang Q, Wang S, Yao Y, Shao L. Determination of amino acid neurotransmitters in rat hippocampi by HPLC-UV using NBD-F as a derivative. Biomed Chromatogr 2014, 28: 459–462.CrossRefPubMed
34.
Pini RT, do Vales LD, Braga Costa TM, Almeida SS. Effects of cafeteria diet and high fat diet intake on anxiety, learning and memory in adult male rats. Nutr Neurosci 2017, 20: 396–408. CrossRefPubMed
35.
Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR. Perforant pathway changes and the memory impairment of Alzheimer’s disease. Ann Neurol 1986, 20: 472–481.CrossRefPubMed
36.
Sze CI, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains. J Neurol Sci 2000, 175: 81–90.CrossRefPubMed
37.
Mohideen SS, Ichihara S, Banu S, Liu F, Kitoh J, Ichihara G. Changes in neurotransmitter receptor expression levels in rat brain after 4-week exposure to 1-bromopropane. Neurotoxicology 2009, 30: 1078–1083.CrossRefPubMed
38.
Lamsa K, Heeroma JH, Kullmann DM. Hebbian LTP in feed-forward inhibitory interneurons and the temporal fidelity of input discrimination. Nat Neurosci 2005, 8: 916–924.CrossRefPubMed
39.
Aoki C, Venkatesan C, Go CG, Mong JA, Dawson TM. Cellular and subcellular localization of NMDA-R1 subunit immunoreactivity in the visual cortex of adult and neonatal rats. J Neurosci 1994, 14: 5202–5222.CrossRefPubMedPubMedCentral
40.
41.
Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 2005, 48: 503–516.CrossRefPubMed
42.
Flavin HJ, Seyfried TN. Enhanced aspartate release related to epilepsy in (EL) mice. J Neurochem 1994, 63: 592–595.CrossRefPubMed
43.
44.
Jia N, Sun Q, Su Q, Dang S, Chen G. Taurine promotes cognitive function in prenatally stressed juvenile rats via activating the Akt-CREB-PGC1alpha pathway. Redox Biol 2016, 10: 179–190.CrossRefPubMedPubMedCentral
45.
Chan CY, Sun HS, Shah SM, Agovic MS, Ho I, Friedman E, et al. Direct interaction of taurine with the NMDA glutamate receptor subtype via multiple mechanisms. Adv Exp Med Biol 2013, 775: 45–52.CrossRefPubMed
46.
Fueta Y, Fukunaga K, Ishidao T, Hori H. Hyperexcitability and changes in activities of Ca2+/calmodulin-dependent kinase II and mitogen-activated protein kinase in the hippocampus of rats exposed to 1-bromopropane. Life Sci 2002, 72: 521–529.CrossRefPubMed
47.
Suda M, Honma T, Miyagawa M, Wang RS. Alteration of brain levels of neurotransmitters and amino acids in male F344 rats induced by three-week repeated inhalation exposure to 1-bromopropane. Ind Health 2008, 46: 348–359.CrossRefPubMed
48.
Mayer ML, Vyklicky L Jr, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature 1989, 338: 425–427.CrossRefPubMed
49.
Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325: 529–531.CrossRefPubMed
50.
Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150: 633–646.CrossRefPubMed
51.
Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol 2010, 119: 89–105.CrossRefPubMed
52.
Alimonti A, Ristori G, Giubilei F, Stazi MA, Pino A, Visconti A, et al. Serum chemical elements and oxidative status in Alzheimer’s disease, Parkinson disease and multiple sclerosis. Neurotoxicology 2007, 28: 450–456.CrossRefPubMed
53.
54.
Zhang XF, Thompson M, Xu YH. Multifactorial theory applied to the neurotoxicity of paraquat and paraquat-induced mechanisms of developing Parkinson’s disease. Lab Investig 2016, 96: 496–507.CrossRefPubMed
55.
Bayer TA, Multhaup G. Involvement of amyloid beta precursor protein (AbetaPP) modulated copper homeostasis in Alzheimer’s disease. J Alzheimers Dis 2005, 8: 201–206; discussion 209–215.CrossRefPubMed
56.
Hayashi Y, Ishibashi H, Hashimoto K, Nakanishi H. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia 2006, 53: 660–668.CrossRefPubMed
57.
Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003, 23: 8692–8700.CrossRefPubMedPubMedCentral
58.
Han RZ, Hu JJ, Weng YC, Li DF, Huang Y. NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury. Neurosci Bull 2009, 25: 367–375.CrossRefPubMedPubMedCentral
59.
Jha S, Srivastava SY, Brickey WJ, Iocca H, Toews A, Morrison JP, et al. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 2010, 30: 15811–15820.CrossRefPubMedPubMedCentral
Metadaten
Titel
NMDA Receptor Antagonist MK801 Protects Against 1-Bromopropane-Induced Cognitive Dysfunction
verfasst von
Lin Xu
Xiaofei Qiu
Shuo Wang
Qingshan Wang
Xiu-Lan Zhao
Publikationsdatum
01.04.2019
Verlag
Springer Singapore
Erschienen in
Neuroscience Bulletin / Ausgabe 2/2019
Print ISSN: 1673-7067
Elektronische ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-018-0321-8

Weitere Artikel der Ausgabe 2/2019

Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina

  • Original Article

Altered Local Field Potential Relationship Between the Parafascicular Thalamic Nucleus and Dorsal Striatum in Hemiparkinsonian Rats

  • Open Access
  • Original Article

Quantification of Tyrosine Hydroxylase and ErbB4 in the Locus Coeruleus of Mood Disorder Patients Using a Multispectral Method to Prevent Interference with Immunocytochemical Signals by Neuromelanin

  • METHOD

Parkinson’s Disease Risk Variant rs1109303 Regulates the Expression of INPP5K and CRK in Human Brain

  • Letter to the Editor

Kir2.1 Channel Regulation of Glycinergic Transmission Selectively Contributes to Dynamic Mechanical Allodynia in a Mouse Model of Spared Nerve Injury

  • Original Article

Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach

  • Review

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Erneut Hinweise für Neuroprotektion durch Gürtelroseimpfung

Ergebnisse eines kürzlich publizierten „natürlichen Experiments“ in Wales legten nahe, dass eine Herpes-Zoster-Impfung das Demenzrisiko senkt. Jetzt hat das Studienteam ähnliche Daten aus Australien publiziert, die in die gleiche Richtung zeigen. Offene Fragen bleiben allerdings so oder so.

Podcast

Leben statt zu Überleben: Post-Intensive-Care-Syndrom

Immer mehr Menschen überleben kritische Erkrankungen. Aber Beatmung, Sedierung und die Eindrücke der Intensivstation hinterlassen Spuren. Das Post-Intensive-Care-Syndrom kann die Folge sein. Es ist nicht nur eine Herausforderung für Kliniken, sondern auch Hausarztpraxen. Mit Allgemeinmediziner Prof. Dr. med. Konrad Schmidt sprechen wir in dieser Folge darüber, wie die Überlebenden wieder ins Leben finden können.

Zeitschrift für Allgemeinmedizin, DEGAM

Ehe schützt nicht vor Demenz

  • 25.04.2025
  • Demenz
  • Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise